Short title: Platelet surface exposure of functional FXIII-A
Introduction
Factor XIII (FXIII) plays an essential role in normal hemostasis where it contributes to the regulation of fibrinolysis, 1-3 the maintenance of pregnancy, 4 wound healing and angiogenesis. 5 The function of FXIII in hemostasis is further emphasized in its deficiency which results in hemorrhage 6, 7 and slow wound healing. 4, 7 FXIII circulates in plasma as a heterotetramer (FXIII-A 2 B 2 ) where the catalytic A (FXIII-A 2 ) subunits circulate almost exclusively in complex with the inhibitory carrier B (FXIII-B 2 ) subunits. 8 FXIII is activated by the combined action of thrombin and Ca 2+ to form the active transglutaminase (TG), FXIIIa. 9, 10 FXIIIa confers stability to the fibrin matrix by crosslinking fibrin, substantially altering its rheologic properties. 11, 12 TGs catalyze formation of covalent ε-(γ-glutamyl) lysyl bonds, 13 where the lysine ε-amino group is cross-linked to the glutamine γ-carboxymide group. 14 γ-Chain cross-linking confers a degree of rigidity to the fibrin network, which is further stabilized by the cross-linking of α-chains 15 to generate high molecular weight polymers. 10, 16 FXIIIa also cross-links inhibitors of fibrinolysis to fibrin, further increasing its insolubility and resistance to plasmin. These inhibitors include α 2 -antiplasmin (α 2 AP); 17 thrombin activatable fibrinolysis inhibitor (TAFI); 18 and plasminogen activator inhibitor-2 (PAI-2). 19 α 2 AP is a serpin inhibitor that forms an irreversible complex with plasmin 20 and interferes with binding of plasminogen to fibrin. 21 FXIIIa cross-links Gln-2 of α 2 AP to Lys-303 of the Aα chain of fibrin(ogen). 22 The crucial role of cross-linked α 2 AP in stabilizing fibrin is demonstrated by the rapid lysis of clots formed in the absence of α 2 AP, 1, 3, 17 or when α 2 AP activity is neutralized. 1 FXIII-A is present in platelets [22] [23] [24] [25] [26] [27] in large quantities; a single platelet contains 60 ± 10 fg 28 making local platelet FXIII-A concentration around 150-fold greater than in plasma. 29 Platelet FXIII-A, also known as cellular FXIII, 30 is largely stored in the cytoplasm 23, 24 and, in contrast to FXIII-A 2 B 2 , can be non-proteolytically activated by Ca 2+ alone. 31 Platelet-rich clots in vivo are much more resistant to lysis than whole blood clots. 32 Platelets are known to stabilize static clots, 33,34 increase high molecular weight α-polymers and γ-γ dimer formation [33] [34] [35] [36] and augment cross-linking of α 2 AP to fibrin. [33] [34] [35] However, it is unclear how platelet FXIII-A elicits these functions, as it is For personal use only. on October 31, 2017. by guest www.bloodjournal.org From not released during activation, 37 and does not follow classical routes of secretion in platelets or other cells. 38 We have previously shown, using thrombi formed under flow, that FXIII increases resistance to fibrinolysis, 39 specifically via cross-linking of α 2 AP to fibrin. 1 Here we show that activated platelets externalize their cytoplasmic pool of FXIII-A onto their membrane. FXIII-A exposed on the platelet surface is functional in cross-linking α 2 AP and confers fibrinolytic resistance to model thrombi formed under flow.
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Methods

Collection of blood and preparation of plasma
Peripheral blood was collected into vacutainers containing acid-citrate-dextrose (ACD) solution A (Greiner Bio-one LTD, Stonehouse, UK); the first 3 ml was discarded. Pooled normal plasma (PNP) that was essentially free of platelets was prepared from 20 normal donors by centrifugation at 1850 x g for 30 minutes at 4 o C.
Platelet-rich plasma (PRP) was prepared by centrifugation at 170 x g for 10 min at 22 o C and platelet-poor plasma (PPP) by centrifugation at 1850 x g for 30 min at 4 o C. 40 
Preparation of washed platelets
Purified platelets were prepared from outdated human apheresis platelets (donated by Scottish National Blood Transfusion Service, Aberdeen, UK) as previously described. 41 Alternatively, platelets were isolated from freshly drawn blood by centrifugation for 15 min at 260 x g at 22 o C to collect PRP. PRP was added to 80 mM trisodium citrate, 52 mM citric acid, 183 mM glucose and 0.1 U/ml apyrase 
Preparation of platelet fractions
Washed apheresis platelets (10 x 10 9 ) were activated with 200 μg/ml equine type 1 collagen (American Biochemical & Pharmaceuticals, Surrey, UK) and 200 µM thrombin receptor activator peptide 6 (TRAP-6) (Sigma-Aldrich) for 5 min at 37 o C. Activated platelets were centrifuged at 13,000 x g and the supernatant, termed platelet releasate, collected. Platelet lysate was prepared by sonicating platelets for For personal use only. on October 31, 2017. by guest www.bloodjournal.org From 30 s in a sonic dismembrator (ARTEK Systems Corporation, Farmingdale, NY, USA). Platelet membranes were prepared from platelet lysates by centrifuging at 12,000 x g to remove unlysed platelets. Supernatants were then ultracentrifuged in a Beckman Coulter Optima TM MAX Ultra-centrifuge at 100,000 x g for 1 h. The supernatant was collected as the platelet cytoplasmic fraction. And the residual pellet, or membrane fraction, resuspended in the original volume of 20 mM Tris-HCl, pH 7.6, 150 mM NaCl, 5 mM glucose and 0.1 M CaCl 2 .
FXIII activity assay
FXIII activity was quantified using an in-house activity assay as previously described 39 with the following modifications. The WHO 1 st international standard FXIII plasma (NIBSC, Hertfordshire, UK) was used. 42 The reaction was performed in 100 mM Tris-HCl, pH 7.4, 1 mM dithiothreitol, 1% BSA, 0.5 mM 5-(biotinamido) pentylamine (Pierce Thermo Fisher Scientific, Rockford, IL,USA), 5 mM CaCl 2 .
Plates were washed with 0.01% Triton-X-100 in 100mM Tris-HCl, pH 7.4 before adding para-nitrophenyl phosphate substrate (Sigma-Aldrich).
Chandler model thrombus lysis
Chandler model thrombus lysis was performed as previously described. 39 PNP, FXIII-depleted plasma or α 2 AP-depleted plasma (both from Affinity Biologicals, Ancaster, ON, Canada) containing fluorescein isothiocyanate (FITC)-labelled fibrinogen (43.5 μg/ml), with a FITC/fibrinogen ratio of approximately 6:1, were recalcified with CaCl 2 (10.9 mM). The loops were rotated for 90 min at 30 r.p.m. Apheresis platelets (5 x10 8 /ml) or platelet fractions at equivalent concentrations were added in some experiments. Initial experiments were performed with lysates prepared by freeze-thawing of apheresis platelets. A non-reversible inhibitor of TG, 39, 43 or a neutralising antibody to α 2 AP (150 μg/mL; Technoclone) 1 were incorporated prior to recalcification. Formed thrombi were washed in 0.9% (w/v) NaCl and bathed at 37 o C in 10 mM Tris, 0.01% Tween 20, pH 7.4 containing 1 μg/ml single-chain tissue-type plasminogen activator (tPA; Genetech, San Francisco, CA, USA). Samples were taken at 30 min intervals for 4 h. Fluorescence was read, excitation 485 nm and emission 528 nm, on a Biotek Instruments Fluorometer. Alternatively, thrombi were 
Flow Cytometry
Freshly isolated platelets were incubated for 45 min with FITC-labelled polyclonal rabbit anti-human FXIII antibody (20 μg/ml; Zedira, Darmstadt, Germany), specific for FXIII-A subunit ( Figure S1 ) or an isotype control (Stratech Scientific Limited). 
Confocal microscopy
Ibidi μ-slide VI 0.4 uncoated chambers were washed with phosphate buffered saline pH 7.4 (PBS). Washed platelets (5 x10 7 /ml) were activated with collagen (20 μg/ml) and TRAP-6 (20 μM) or collagen and thrombin (100 nM) in the presence of FITClabelled polyclonal rabbit anti-human FXIII (20 μg/ml), Alexa-fluor ® 647 Annexin-V conjugate (1/20; Life Technologies, Paisley, UK) and CaCl 2 (2 mM) and allowed to adhere to slides for 5 min before analysis. Images were taken using brightfield and at excitation wavelengths of 488 nm and 633 nm on a Zeiss LSM710 confocal microscope with 63x 1.40 oil immersion objective and analyzed using Zen 2012 software.
Statistical analysis
Rates of lysis (FU/min -1 ) for Chandler model thrombi were determined by best fit of the slope to a centered second order polynomial quadratic in GraphPad Prism ® 5.04 and used to calculate fold differences in lysis. Statistical analysis was performed on FXIII activity assay data and Chandler model thrombi lysis rates using one-way analysis of variance with Dunnett's Multiple comparison post-hoc test. Paired t-tests were used to analyze flow cytometry results. P < 0.05 was considered to be significant.
Results
Platelet TG stabilizes FXIII-depleted thrombi
Total FXIII activity generated in plasma is 1.6-fold higher in PRP (1.5 ± 0.05 IU/ml) compared to PPP (0.9 ± 0.12) (P < 0.005, n=4), indicating that platelets represent an important pool of potential activity. No activity could be detected in FXIII-depleted plasma. We therefore analyzed whether platelet lysates could stabilize thrombi against the rapid lysis observed in the absence of FXIIIA 2 B 2 . 39 Addition of platelet lysates stabilized FXIII-depleted thrombi in a dose-dependent manner ( Figure 1A) .
The experiments described above were performed on frozen platelet preparations, but fresh apheresis platelets still produced a 2.3-fold (P < 0.001) stabilizing effect on FXIII-depleted thrombi and were used throughout the rest of the study. Inclusion of a TG inhibitor 39, 43 abrogated the stabilizing effect of platelets in FXIII-depleted thrombi ( Figure 1B ; P < 0.01), revealing a TG-mediated effect. TG2 antigen was below the limit of detection in Western blots of platelet lysates (1 x10 9 ) (data not shown), it is therefore assumed that the source of TG activity is platelet FXIII-A. Thrombi formed with mixtures of pooled normal and FXIII-depleted plasma lysed rapidly until FXIII-A 2 B 2 concentrations reached approximately 20% of normal ( Figure 1C ). In contrast, no defect in lysis was observed in the presence of platelets (2.5 x10 8 /ml) ( Figure   1C ). α 2 AP is required for platelet FXIII-A to stabilize thrombi Cross-linking of α 2 AP is essential for FXIII-A 2 B 2 to exhibit antifibrinolytic activity. 1 Here we use α 2 AP as a probe to examine the functional activity of platelet FXIII-A.
FXIII-depleted thrombi were formed with platelets ± an antibody to α 2 AP that inhibits activity but not its cross-linking to fibrin. 1 Inclusion of the neutralizing antibody to α 2 AP reduced the lag time to lysis, resulting in a more linear curve, but the overall change in lysis rate was not significantly different ( Figure 2A ). However, the antibody substantially reduced the stabilizing effect of platelets on FXIII-depleted thrombi ( Figure 2A ; P < 0.001). Similarly, thrombi formed from α 2 AP depleted plasma lysed at a rapid rate compared to thrombi formed with PNP, but addition of platelets failed to stabilize against lysis ( Figure 2B ). Incorporation of a TG inhibitor also had no effect on the lysis of α 2 AP-depleted thrombi formed ± platelets. Cross-linking of α 2 AP For personal use only. on October 31, 2017. by guest www.bloodjournal.org From to fibrin and fibrin-fibrin crosslinking was also demonstrated by Western blotting, using extracts of FXIII-depleted thrombi formed ± platelets ( Figure 2C ). These data indicate that platelet FXIII-A is functional in cross-linking α 2 AP to fibrin and stabilizing against lysis.
Platelet activation is essential for stabilisation of thrombi
Inhibition of platelet activation with theophylline and prostaglandin E1 41 prevented platelets from stabilizing FXIII-depleted thrombi (P < 0.001). In line with this, inclusion of a TG inhibitor had no additional effect on lysis ( Figure 3A) . These results support our observation that platelets expose FXIII-A during activation.
Pre-activating platelets for 5 min with TRAP-6 and collagen prior to thrombus formation stabilized FXIII-depleted thrombi against lysis (P < 0.001; Figure 3B ).
However, this effect was reduced following 1 h pre-activation ( Figure 3B ).
Incorporation of TG inhibitor into thrombi formed with platelets pre-activated for 1 h did not increase lysis. Loss of FXIII-A activity following pre-activation by TRAP-6/ collagen was examined by activity assay in the absence of exogenous thrombin.
Maximal FXIIIa activity was detected when platelets were pre-activated for 5 min before incorporation into the cross-linking assay (0.56 ± 0.07 IU/ml), but decreased to 0.27 ± 0.07 IU/ml (P < 0.01) after 15 min of pre-activation and was almost undetectable after 1 h (0.05 ± 0.02, P < 0.001; Figure 3C ). These data indicate that FXIII-A activity on the activated platelet membrane is unstable over time.
Platelet FXIII is stored in the cytoplasm and membrane fractions
FXIIIa activity derived from unstimulated lysed platelets (0.77 IU/ml) was largely contained in the platelet cytoplasm (0.91 IU/ml), with only a small proportion found in the platelet membrane fraction (0.05 IU/ml). Minimal FXIIIa activity were detected in the platelet releasate (0.01 IU/ml; Figure 4A ). FXIIIa activity derived from lysed platelet preparations closely correlates with that observed in platelets activated for 5 min ( Figure 3C ), suggesting that the majority of platelet FXIII-A is exposed upon activation. FXIII-A antigen was detected by Western blotting in lysed platelet preparations and in membrane and cytoplasmic fractions, all at concentrations equivalent to 2 x10 9 plts/ml. In contrast, FXIII-A was barely detectable in platelet releasates ( Figure 4B ). FXIII-B antigen was not detected in lysed platelets or isolated fractions, confirming that FXIII-A is platelet-derived and is not from contaminating FXIII-A 2 B 2 on the surface of platelets, or due to uptake of the plasma pool into αgranules. Isolated platelet fractions were incorporated into FXIII-depleted thrombi in concentrations equivalent to 5 x10 8 platelets/ml ( Figure 4C. ). Platelet lysate (P < 0.001) and platelet cytoplasm (P < 0.001) derived from unstimulated platelet preparations stabilized FXIII-depleted plasma thrombi, 11.6-fold and 8.8-fold respectively. The addition of unstimulated platelet membranes to FXIII-depleted thrombi partially stabilized thrombi against lysis (2-fold; P < 0.01). Addition of releasates from stimulated platelets to FXIII-depleted thrombi were unable to stabilize against lysis. Due to the unstable nature of FXIIIa on the surface of activated platelets we were unable to quantify activity in isolated membrane and cytoplasmic fractions following activation.
Platelet FXIII-A is expressed on the surface of activated platelets
We next examined exposure of FXIII-A on activated platelets by flow cytometry.
Stimulation of platelets with thrombin/CVX (49.8% ± 8.8; P < 0.01) and to a lesser extent TRAP-6/CVX (39.2% ± 3.6; P < 0.05) significantly increased exposure of FXIII-A compared to unstimulated platelets (13.7% ± 6.1; Figure 5A -B). Single agonists, including ADP, arachidonic acid, CVX, TRAP-6 and thrombin increased platelet FXIII exposure compared to unstimulated platelets, but the only significant increase observed was with thrombin (data not shown). A small level of background staining, equivalent to 6% or less, was evident with the isotype control. Inclusion of GPRP to inhibit fibrin polymerisation did not alter FXIII-A expression levels in TRAP-6/CVX stimulated platelets (41.4% ± 2.9; not shown), but resulted in a 6.4% reduction in total FXIII-A expression on thrombin/CVX stimulated platelets (43.4% ± 9.5; not shown). Western blot analysis revealed that FXIII-A was present in the platelet membrane pre-and post-stimulation with TRAP-6/collagen, however this approach does not differentiate between proteins on the inner and outer leaflets of the membrane ( Figure 5C ). In contrast, FXIII-A could not be detected in the cytoplasm post-stimulation, suggesting this pool translocates during platelet activation.
FXIII-A exposure on the surface of activated platelets was also examined by fluorescence confocal microscopy. Two subpopulations of activated platelets were 
Discussion
This study defines the contribution of platelet FXIII-A to the inhibtion of fibrinolysis.
We show that physiological platelet concentrations stabilize FXIII-depleted thrombi against fibrinolysis. The stabilizing effect was largely TG-mediated, as it was abrogated by a specific TG inhibitor. 39 Activity was attributed to FXIII-A, as TG2 antigen was undetectable in human platelets, consistent with the lack of TG2 mRNA. 44 Our data support previous observations that platelets increase mechanical stability 45 and the number of high molecular weight α-polymers and γ-γ dimers 33-36 in FXIII-depleted clots, while limiting fibrinolysis. 33, 34 We quantitatively assessed the subcellular localisation of platelet FXIII-A and have shown for the first time that cytoplasmic FXIII-A is externalized onto the activated platelet membrane.
Expression of PS and platelet-derived FXIII-A on resting and activated platelets was
visualized using confocal microscopy and flow cytometry. Approximately 50 % of stimulated platelets express FXIII-A on their surface. FXIII-A was previously detected, but not quantified, on activated platelets by flow cytometry. 46 Nagy et al. 47 reported that less than 5% of platelets expose FXIII-A after TRAP stimulation, values that differ markedly from this study. Differences in experimental set-up, including activation time and the sole use of TRAP-6, may account for these discrepancies.
We only observed a significant increase in FXIII-A exposure on platelets when thrombin or dual agonists were used. Strong activation of platelets with dual agonists generates a large intracellular Ca 2+ spike 48 and a specific population, termed coated platelets. 49, 50 Platelet TG activity is required for formation of coated platelets. 51, 52 However, they are detected in FXIII-deficient mice, which interestingly exhibit higher total cellular TG activity compared to wild-type mice, suggesting a possible compensatory mechanism. 52 Upon activation we observe a sub-population of PS-positive 'balloon-shaped' procoagulant platelets characterised by a protruding 'cap', consistent with previous observations. 48, 53 We found that FXIII-A is expressed exclusively on 'caps' of PS-positive 'balloon-shaped' platelets, in contrast to its wider distribution on PS-negative platelets. Secreted fibrinogen has also been detected in 'caps' on the platelet surface 53 suggesting co-localisation of FXIII-A and fibrin(ogen).
Interestingly, GPRP only slightly reduced the number of thrombin/CVX stimulated platelets exposing FXIII-A and had no effect on platelets stimulated with TRAP-6/
CVX. This suggests that a small pool of FXIII-A associates with polymerized fibrin on
For personal use only. on October 31, 2017. by guest www.bloodjournal.org From the membrane, but does not rule out an interaction with fibrinogen or monomeric fibrin. It is possible that fibrin(ogen) acts as an interface for FXIII-A to translocate from the platelet surface into the surrounding fibrin network extending from platelet aggregates.
FXIII-A is localized in the cytoplasmic fraction of resting platelets, with only a small contribution from the membrane, consistent with previous reports. 23,24,26 FXIII-A in these sub-cellular fractions was functional, as evidenced in the activity assay and in their ability to stabilize FXIII-depleted thrombi against lysis. FXIII has previously been detected in platelet releasates, 54, 55 but these observations are not consistent with our data or other reports. 23,24,37,46 FXIII-A levels are normal in platelets derived from patients with grey-platelet syndrome 25 and plasma FXIII levels are unchanged in thrombocytopenic mice. 38 Together these data indicate a very minor contribution of α-granule FXIII-A 2 B 2 to the overall TG activity derived from platelet preparations.
Platelet activation is essential for FXIII-A-mediated stabilisation of FXIII-depleted thrombi. FXIII-A activity assays on platelets pre-activated with TRAP-6/collagen are carried out in the absence of exogenous thrombin, suggesting that FXIII-A is nonproteolytically activated by the high Ca 2+ levels associated with platelet stimulation.
Strong stimulation of platelets depletes the cytoplasm of FXIII-A and allows its
accumulation on the outer membrane surface, as shown by flow cytometry and confocal microscopy. Inhibition of platelet activation and aggregation prior to thrombus formation prevented stabilization of FXIII-depleted thrombi. FXIII-A activity exposed on platelet membranes was unstable and was almost undetectable after a 1 h pre-activation, consistent with previous reports on plasma FXIII. 10, 56 The unstable nature of FXIII-A on the platelet membrane may have important physiological consequences, as it would prevent on-going cross-linking which is known to increase fibrinolytic resistance of thrombi. 36, 57 Thrombi formed under flow are a sensitive model in which to examine the effects of cross-linking 39 and inhibitors 58 on fibrinolysis. We have previously shown that α 2 APdepleted thrombi, or normal thrombi formed with an antibody to α 2 AP, lyse rapidly irrespective of FXIII concentration, thereby illustrating the essential contribution of cross-linked α 2 AP to thrombus stability. 1 Here we show that platelet FXIII-A also mediates cross-linking of α 2 AP to fibrin. Platelets have been implicated in cross-For personal use only. on October 31, 2017. by guest www.bloodjournal.org From linking of α 2 AP in purified clots and plasma, 34,35 but their contribution was considered minor. The antifibrinolytic effect of platelets was substantially reduced in the absence of functional α 2 AP. Platelets also contain a pool of PAI-1 40 which may account for the small remaining effect on stabilization of FXIII-depleted thrombi. These data again underscore the principal role of cross-linked α 2 AP in regulating fibrinolysis. Activated platelets do not externalize their cytoplasmic pool of FXIII-A by classical release mechanisms. 37, 38 One potential mechanism of FXIII-A transport to the membrane could be via sphingomyelin (SM)-rich lipid rafts. SM-rich rafts act as signalling platforms on the platelet membrane between intra-and extracellular clot retraction machinery. FXIII-A is highly expressed in the membrane raft fraction in stimulated but not resting platelets. 59 Alternatively, secretion could be mediated by golgi matrix protein 130 (GP130), which co-localizes with FXIII-A in macrophages.
GP130 functions in non-classical protein secretion to the plasma membrane prior to excretion through membrane pores. 38 Platelet-derived tissue factor pathway inhibitor (TFPI) is exposed on activated coated platelets by an unknown mechanism. Like FXIII-A, TFPI is not localized in platelet granules and appears to be of cytoplasmic origin. 60 Platelet microvesicles, released upon activation 61, 62 , contain cytoplasmic material, including FXIII-A, and could be implicated in its secretion. 62 However, the latter release mechanisms are not consistent with our observations that FXIII-A resides in 'caps' on the membrane surface of activated platelets. Further studies are required to elucidate the precise signalling mechanisms involved in externalization of FXIII-A on activated platelets.
The fibrin network immediately adjacent to platelet aggregates is extremely resistant to lysis. [63] [64] [65] [66] This is attributed to the tightly contracted fibrin network; however, it may also result from cross-linking of additional α 2 AP to fibrin due to the high local concentration of FXIII-A. It has recently been shown that supplementing blood of thrombocytopenic patients with FXIII, TAFI or fibrinogen increases clot strength and decreases lysis. 67 These proteins are all contained in platelets and indicate that local concentrations of these proteins, including surface bound FXIII-A, mediate thrombus stabilization. Indeed, an increase in FXIII-A activity over time was observed on incorporation of intact platelets into plasma clots. 37 We show that inhibiting platelet activation or FXIIIa activity directly dramatically reduces stabilization of thrombi by For personal use only. on October 31, 2017. by guest www.bloodjournal.org From platelets. The impact of platelet FXIII-A on thrombus stabilization suggests it may translocate from the activated membrane into the adjacent fibrin network, but the extent of diffusion requires further clarification.
Under certain circumstances the antifibrinolytic effect of platelet FXIII-A may be central in stabilizing thrombi, such as during surgery when plasma FXIII-A 2 B 2 levels rapidly decline 67 or following cardiopulmonary bypass with extracorporeal circuit.
Acquired FXIII deficiency can also occur in the absence of surgery, such as in a case of aortic dissection where plasma FXIII-A 2 B 2 levels deplete to 30-35% of normal. 68 FXIII-B subunit deficiency results in loss of FXIII-A in plasma, presumed to be due to instability 69-71 , but levels of platelet FXIII-A are normal. 70,72 FXIII-B deficiency is associated with milder symptoms than FXIII-A deficiency in humans 69 and FXIII-B knock-out mice 73 . This is thought to be due to the remaining levels of free FXIII-A in the plasma, however, our results suggest that platelet FXIII-A may also compensate under these circumstances. Our data demonstrate that when plasma FXIII-A 2 B 2 is below 20% of normal the antifibrinolytic effect of platelet FXIII-A becomes apparent with levels of 10% of normal being statistically significant. High arterial shear rates result in increased platelet adhesion and deposition, 74 but reduced accumulation of fibrinogen in forming thrombi. 74, 75 In these platelet-rich thrombi cellular sources of fibrin(ogen) and FXIII-A may contribute to stabilizing against fibrinolysis.
In conclusion, our study is the first to show that activated platelets externalize their pool of cytoplasmic FXIII-A in response to strong stimulation. FXIII-A exposed on the stimulated platelet membrane is active and is potentially transferred into the fibrin network adjacent to platelet aggregates. This mechanism may be important in the initial stabilization of the platelet-plug at the site of injury. The ability of FXIII-A to stabilize fibrin against lysis is entirely dependent on the presence of functional α 2 AP, consistent with our previous studies on FXIII-A 2 B 2 . Further work is necessary to define the exact mechanism involved in translocation of FXIII-A across the platelet membrane and the signalling events that elicit these responses. 
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